Garrone S, Radetti G, Sidoti M, Bozzola M, Minuto F, Barreca A
Department of Endocrinology and Metabolism, University of Genova, Genova I-16132, Italy.
J Clin Endocrinol Metab. 2002 Dec;87(12):5455-60. doi: 10.1210/jc.2002-020614.
The height of subjects with constitutionally tall stature (CTS) is at least 2 SD above the mean of subjects of the same age and sex. Apart from a few discordant data on the role of GH and its direct mediator, IGF-I, no studies have been conducted on other components of the IGF system, which also condition the bioavailability and activity of IGF-I. We, therefore, investigated the possibility that other components of the IGF system might play a role in determining the increased growth velocity seen in CTS. To this end, we evaluated the behavior not only of IGF-I but also of IGF-II, IGF-binding protein (IGFBP)-3, and acid-labile subunit, the subunits that constitute the main IGF complex in circulation (150-kDa complex), as well as of IGFBP-1 and IGFBP-2, which are negatively regulated by GH and, like IGFBP-3, able to influence the bioavailability of the IGFs. The study was performed on 22 prepubertal subjects affected by CTS (16 males and 6 females), aged 2.8-13.3 yr (6.8 +/- 0.5 yr, mean +/- SEM). Thirty-seven normal prepubertal subjects (16 males and 21 females) aged between 2.2 and 13.3 yr (6.7 +/- 0.5 yr), who were comparable in socioeconomic and nutritional terms, served as controls. From the auxological point of view, subjects with CTS differed significantly from controls only in terms of growth velocity (HV-SD score; CTS, 1.8 +/- 0.3; controls, 0.4 +/- 0.2; P < 0.0001) and height (H-SD score; CTS, 3.1 +/- 0.1; controls, 0.4 +/- 0.2; P < 0.0001). The results demonstrated that the concentrations of IGF-I (27.3 +/- 2.0 nmol/liter), IGFBP-3 (66.9 +/- 3.8), and acid-labile subunit (216.8 +/- 13.6) in CTS-affected subjects were not significantly different from those determined in controls (25.0 +/- 2.9, 74.4 +/- 4.1, and 241.0 +/- 11.9, respectively). By contrast, IGF-II levels proved significantly higher in CTS subjects (IGF-II: 87.2 +/- 3.4 vs. 52.4 +/- 2.3, P < 0.0001). Chromatographic analysis, performed after acid treatment of pooled sera, showed only the presence of normal 7.5-kDa IGF-II in both CTS subjects and controls. In comparison with controls, CTS children showed a lower concentration of IGFBP-1 (1.6 +/- 0.3 vs. 4.1 +/- 0.7, P = 0.03) and a higher concentration of IGFBP-2 (14.3 +/- 1.8 vs. 9.6 +/- 1.1, P = 0.03). The IGFs (IGF-I and -II)/IGFBPs (-1 + -2 + -3) molar ratio was significantly higher (P < 0.0001) in CTS children than in controls. In particular, the IGF-II/IGFBP ratio (P < 0.0001) was responsible for the excess of the IGF peptide in relation to the concentrations of IGFBPs and, therefore, for the increase in the potentially bioactive free form of the IGFs. Moreover, the IGFBP-3/IGF molar ratio was significantly reduced, being less than 1 in CTS subjects (0.6 +/- 0.1 vs. 1.1 +/- 0.1), so that a quantity of IGF peptides lack sufficient IGFBP-3 to form the 150-kDa complex with which are normally sequestered in the vascular compartment. The data show that in CTS: 1) the most GH-dependent components of the IGF system are normal, consistent with the finding of a normal GH secretory state; 2) the less GH-dependent IGF-II is significantly increased, in agreement with the finding of a relationship between high levels of IGF-II and overgrowth in some syndromes; and 3) the IGF/IGFBP molar ratio is increased, and, therefore, a greater availability of free IGF for target tissues may be responsible for overgrowth in CTS.
体质性身材高大(CTS)受试者的身高至少比同年龄、同性别的受试者平均身高高出2个标准差。除了关于生长激素(GH)及其直接介质胰岛素样生长因子-I(IGF-I)作用的一些不一致数据外,尚未对IGF系统的其他成分进行研究,而这些成分也会影响IGF-I的生物利用度和活性。因此,我们研究了IGF系统的其他成分是否可能在决定CTS中观察到的生长速度加快方面发挥作用。为此,我们不仅评估了IGF-I的情况,还评估了IGF-II、IGF结合蛋白(IGFBP)-3和酸不稳定亚基,这些亚基构成了循环中主要的IGF复合物(150 kDa复合物),以及IGFBP-1和IGFBP-2,它们受GH负调控,并且与IGFBP-3一样,能够影响IGF的生物利用度。该研究对22名受CTS影响的青春期前受试者(16名男性和6名女性)进行,年龄在2.8 - 13.3岁(6.8±0.5岁,平均值±标准误)。37名年龄在2.2至13.3岁(6.7±0.5岁)之间、社会经济和营养状况相当的正常青春期前受试者(16名男性和21名女性)作为对照。从体格学角度来看,CTS受试者与对照组仅在生长速度(身高增长速度标准差评分;CTS组,1.8±0.3;对照组,0.4±0.2;P < 0.0001)和身高(身高标准差评分;CTS组,3.1±0.1;对照组,0.4±0.2;P < 0.0001)方面存在显著差异。结果表明,受CTS影响的受试者中IGF-I(27.3±2.0 nmol/L)、IGFBP-3(66.9±3.8)和酸不稳定亚基(216.8±13.6)的浓度与对照组(分别为25.0±2.9、74.4±4.1和241.0±11.9)相比无显著差异。相比之下,CTS受试者的IGF-II水平显著更高(IGF-II:87.2±3.4对52.4±2.3,P < 0.0001)。对混合血清进行酸处理后进行的色谱分析表明,CTS受试者和对照组中均仅存在正常的7.5 kDa IGF-II。与对照组相比,CTS儿童的IGFBP-1浓度较低(1.6±0.3对4.1±0.7,P = 0.03),而IGFBP-2浓度较高(14.3±1.8对9.6±1.1,P = 0.03)。CTS儿童中IGF(IGF-I和-II)/IGFBP(-1 + -2 + -3)摩尔比显著高于对照组(P < 0.0001)。特别是,IGF-II/IGFBP比值(P < 0.0001)导致IGF肽相对于IGFBP浓度过量,因此导致IGF潜在生物活性游离形式增加。此外,CTS受试者中IGFBP-3/IGF摩尔比显著降低,小于1(0.6±0.1对1.1±0.1),以至于一定量的IGF肽缺乏足够的IGFBP-3来形成通常在血管腔中隔离的150 kDa复合物。数据表明,在CTS中:1)IGF系统中最依赖GH的成分正常,这与GH分泌状态正常的发现一致;2)较少依赖GH的IGF-II显著增加,这与一些综合征中IGF-II水平升高与生长过度之间的关系的发现一致;3)IGF/IGFBP摩尔比增加,因此,游离IGF对靶组织的更大可用性可能是CTS中生长过度的原因。